Canadian study backs On-X heart valves
This article was originally published in Clinica
Executive Summary
The mechanical heart valves developed by On-X Life Technologies are not associated with thromboembolism or haemorrhage in the medium term, a trial has found. On-X has developed two slightly different versions of the valve: an aortic and a mitral valve, both of which come in different sizes to accommodate the patient's anatomy.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.